News | December 31, 2024
Schizophrenia in Children: Understanding Early-Onset Schizophrenia
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Also received tentative approval for 137 mg
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Subscribe To Our Newsletter & Stay Updated
